Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases

October 16, 2024

Article

Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.

Dr Lin on the Importance of the DESTINY-Breast12 Trial for T-DXd Use in HER2+ Breast Cancer With Brain Metastases

October 16, 2024

Video

Nancy U. Lin, MD, discusses the importance of the DESTINY-Breast12 trial of T-DXd in patients with HER2+ breast cancer with vs without brain metastases.

Dana-Farber Cancer Institute Delivers ‘Simple Immediate Impact’ to Patient Comfort Using Weighted Blankets

October 14, 2024

Article

Dana-Farber Cancer Institute has used weighted blankets to aid in patient care.

Study Finds Doctors and Patients Interested in Environmental Impact of Health Care Decisions

October 09, 2024

Article

In focus groups conducted in the US, doctors and patients expressed openness to considering environmental factors when discussing treatment options.

Cigall Kadoch, PhD, Wins Prestigious Blavatnik National Award

October 07, 2024

Article

Cigall Kadoch, PhD, has been named as the Laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences.

Criteria for Cancer Clinical Trials and Treatment Regimens Place Patients of African and Middle Eastern Ancestry at a Disadvantage Due to Natural Blood Test Variability, Study Finds

October 04, 2024

Article

Clinical trials may be inappropriately excluding some people with "Duffy-null phenotype," a trait found in people of African or Middle Eastern descent.

Dr Machaalani on the Incidence of ERBB2 Amplifications Across Race, Sex, and Cancer Type

October 04, 2024

Video

Marc Machaalani, MD, discusses an investigation into the distribution of ERBB2 amplifications across sex, race, and varying cancer types.

Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer

October 02, 2024

Article

Research from Dana-Farber Cancer Institute clinicians showed that adding nivolumab to tivozanib did not improve survival for patients with advanced RCC.

Dr Ng on Factors That Influence Later-Line Treatment Decisions in mCRC

September 30, 2024

Video

Kimmie Ng, MD, MPH, discusses factors of consideration for later-line treatment decisions in patients with refractory metastatic colorectal cancer.

Breast Cancer Experts Spotlight Early-Phase and Real-World Research at the 2024 ESMO Congress

September 26, 2024

Article

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

Dr Choueiri on Initial Efficacy Data With NKT2152 in Pretreated ccRCC

September 26, 2024

Video

Toni K. Choueiri, MD, discusses early findings from a phase 1/2 trial evaluating NKT2152 in previously-treated advanced clear cell renal cell carcinoma.

ADC Found Effective Against Brain Metastases in Patients with HER2+ Breast Cancer

September 26, 2024

Article

T-DXd shows substantial antitumor activity in brain metastases in patients with HER2-positive breast cancer in a major international clinical trial.

Dr Ng on the Addition of Vitamin D to Bevacizumab Plus Chemotherapy in mCRC

September 26, 2024

Video

Kimmie Ng, MD, MPH, discusses the addition of vitamin D to standard chemotherapy plus bevacizumab in patients with untreated metastatic colorectal cancer.

Genitourinary Oncologists Break Down Data from Lesser-Known Studies at the 2024 ESMO Congress

September 26, 2024

Article

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

Dr Partridge on Unique Treatment Challenges for Young Patients with ER+/Node-Positive Breast Cancer

September 25, 2024

Video

Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.

High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer

September 23, 2024

Article

The SOLARIS trial results suggest that high-dose vitamin D3 cannot be recommended as a treatment for patients with untreated metastatic colon cancer.

Dr Morgans on Previously Reported Data From the ARAMIS Trial in nmCRPC

September 18, 2024

Video

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr Tarantino on Advances Allowing for Tailored Treatment in HER2+ Breast Cancer

September 16, 2024

Video

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCC

September 15, 2024

Video

Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.

Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS Metastases

September 14, 2024

Video

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.